Cognitive Change
Conditions
Brief summary
Transcranial Light Therapy involves non-invasive and invisible beams of light that increase energy metabolism in the brain. Transcranial light therapy has been found to promote brain metabolism. The purpose of the study is: To asses the change in cerebral blood flow induced by the Transcranial Continuous and Pulse Near-Infrared Light Therapy in healthy subjects. To correlate with cognitive performance the change in cerebral blood flow induced by the Transcranial Continuous and Pulse Near-Infrared Light Therapy in healthy subjects. To correlate with skin pigmentation the change in cerebral blood flow induced by the Transcranial Continuous and Pulse Near-Infrared Light Therapy in healthy subjects. To assess the safety and tolerability of the Transcranial Continuous and Pulse Near-Infrared Light Therapy in healthy subjects
Detailed description
During study visits a clinician applies transcranial light therapy to both sides of a participant's forehead for about 30 minutes. The study involves, 1 screening visit which may last up to 3 hours, 3 transcranial light therapy treatment visits, and 1 posttreatment visit (5 total visits to the Massachusetts General Hospital). All eligible participants will have 1 visit with continuous light, 1 visit with pulsed light, and 1 visit with sham light. Cerebral blood flow will be measured before and after each light session using DCS-spectroscopy. During sham transcranial light therapy visits, the transcranial light therapy device will not produce near infrared waves (e.g., light energy that cannot penetrate the skin and cranium). The participant will not know which treatment is received at each visit.
Interventions
Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
Sponsors
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Participant receives all three types of light: continuous, pulse, and sham. They do not know when they receive each type of light, but they do know that they will receive all three.
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subjects age at screening will be between 18 and 70 years old (inclusive). 2. Women of child-bearing potential must use a double-barrier method for birth control (e.g. condoms plus spermicide) if sexually active. 3. Subject Informed Consent obtained in writing in compliance with local regulations prior to enrollment into this study. 4. The subject is willing to participate in this study for at least 5 weeks.
Exclusion criteria
1. The subject is pregnant or lactating. 2. The subject is on any psychotropic medication. 3. Psychotherapy is exclusionary unless the subject has had at least 8 weeks of treatment prior to the screening visit. 4. Any current psychiatric disorder (per SCID assessment) 5. Substance or alcohol dependence or abuse in the past 6 months. 6. History of a psychotic disorder or psychotic episode (current psychotic episode per SCID assessment). 7. Bipolar affective disorder (per SCID assessment). 8. Unstable medical or neurological illness, defined as any illness which is not well-controlled with standard-of-care medications (e.g., insulin for diabetes mellitus, HCTZ for hypertension). 9. Suicidal or homicidal ideation as determined by SCID screening. 10. The subject has a significant skin condition (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on the subject's scalp that is found to be in proximity to any of the procedure sites. 11. The subject has an implant of any kind in the head (e.g. stent, clipped aneurysm, embolised Arteriovenous Malformation (AVM), implantable shunt - Hakim valve). 12. Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment (in US: Visudyne (verteporfin) - for age related macular degeneration; Aminolevulinic Acid- for actinic keratoses; Photofrin (porfimer sodium) - for esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA)- for non-melanoma skin cancer) 13. Recent history of stroke (90 days). 14. Personality traits that rend the subject unsuitable for the study, based on the investigators' clinical judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Cerebral Blood Flow (Baseline to Week 5) | 5 weeks | Measured using Diffuse Correlation Spectroscopy (DCS) signal. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Accuracy on N-Back Task (Baseline to Week 5) | 5 weeks | The N-Back task is a measure of working memory. Participants are presented a sequence of stimuli and they must decide if the current stimulus is the same as the one presented 2 trials ago. Accuracy was measured as a percentage of correct to incorrect trials. |
| Number of Participants With Treatment-Emergent Adverse Events | 5 weeks | The safety endpoints will evaluate any reported adverse events within one week from each sessions of TLT. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Transcranial Light Therapy All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.
Transcranial Light Therapy: Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000) | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | Transcranial Light Therapy |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants |
| Age, Continuous | 28.6 years STANDARD_DEVIATION 12.9 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 6 Participants |
| Region of Enrollment United States | 10 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 10 |
| other Total, other adverse events | 3 / 10 |
| serious Total, serious adverse events | 0 / 10 |
Outcome results
Primary
Change in Cerebral Blood Flow (Baseline to Week 5)
Measured using Diffuse Correlation Spectroscopy (DCS) signal.
Time frame: 5 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Transcranial Light Therapy | Change in Cerebral Blood Flow (Baseline to Week 5) | 2.15 mm2/s | Standard Deviation 1.76 |
Secondary
Change in Accuracy on N-Back Task (Baseline to Week 5)
The N-Back task is a measure of working memory. Participants are presented a sequence of stimuli and they must decide if the current stimulus is the same as the one presented 2 trials ago. Accuracy was measured as a percentage of correct to incorrect trials.
Time frame: 5 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Transcranial Light Therapy | Change in Accuracy on N-Back Task (Baseline to Week 5) | -4.49 accuracy percentage | Standard Deviation 20.84 |
Secondary
Number of Participants With Treatment-Emergent Adverse Events
The safety endpoints will evaluate any reported adverse events within one week from each sessions of TLT.
Time frame: 5 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Transcranial Light Therapy | Number of Participants With Treatment-Emergent Adverse Events | 3 Participants |